CoChat

Complete response in multiple myeloma: Clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation

Open access
Kyle, Robert A., Leong, Traci, Li, Shuli, Oken, Martin M., Kay, Neil E., Van Ness, Brian, Greipp, Philip R. · 2006 · Cancer
Cited by 62

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The importance of obtaining a complete response (CR) in multiple myeloma (MM) treated with chemotherapy is unclear. METHODS: The Eastern Cooperative Oncology Group evaluated 653 previously untreated patients with active MM randomized to vincristine, carmustine (BCNU), melphalan, cyclophosphamide, and prednisone (VBMCP), to VBMCP and recombinant interferon alfa‐2 (INFα‐2), or to VBMCP and high‐dose cyclophosphamide. RESULTS: Objective response was achieved in 420 (67%) of the 628 eligible patients, and 85 (14%) achieved a CR. Patients receiving VBMCP and recombinant INFα‐2 had a significantly higher CR (18%) than those receiving VBMCP alone (10%) (P = .02). The CR rate for VBMCP and high‐dose cyclophosphamide was 12%. Median duration of survival was 3.5 years for all eligible patients, and the estimated 5‐year survival rate was 31%. The median duration of survival from the date of objective response was 5.1 years for those who achieved a CR and 3.3 years for those with a partial response (P < .0001). The median postresponse survival was 6.6 years in the 21 patients in CR with nonclonal disease and 4.4 years in the 11 patients in CR who had persistent clonal disease. All patients with negative immunofixation results and nonclonal plasma cells in whom polymerase chain reaction was performed had a positive result (presence of tumor DNA). CONCLUSION: Patients in whom a CR was achieved had a longer survival than those who had a partial response. Cancer 2006. © 2006 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.21804

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 62

Metadata

Authors
Kyle, R. A., Leong, T., Li, S., Oken, M. M., Kay, N. E., Van Ness, B., & Greipp, P. R.
Venue
Cancer
Publisher
Wiley
Published
2006-03-24
Volume
106
Issue
9
Pages
1958-1966
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2163129932
Cited by
62
References
1
FWCI
5.76
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Complete response in multiple myeloma: Clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. https://app.cochat.ai/papers/10.1002/cncr.21804
The paper
Kyle, R. A., Leong, T., Li, S., Oken, M. M., Kay, N. E., Van Ness, B., & Greipp, P. R. (2006). Complete response in multiple myeloma: Clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. Cancer. https://doi.org/10.1002/cncr.21804

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.